Tuesday, 11 December 2018

Eurocine Vaccines' Immunose(TM) FLU Shows Good Safety in Older Adults

08 August 2018 | News

The study was conducted during the influenza season 2017/2018 with the purpose to evaluate safety and tolerability

Eurocine Vaccines announced good safety and tolerability in older adults, in the second clinical phase I/II study including their quadrivalent influenza vaccine candidate.


Immunose™ FLU is a novel nose drop formulation based on the company´s technology Endocine™ and inactivated split influenza antigens.


I am very happy that we have once again confirmed good safety, this time in older adults, a population in need of better influenza vaccines.


Now we look forward to the immunological results, which are expected in October, says Dr. Anna-Karin Maltais, CSO, Vice President R&D.


The study was conducted during the influenza season 2017/2018 with the purpose to evaluate safety and tolerability, as well as serological and mucosal immune responses to four influenza strains in older adults aged 50-75.


A total of 298 subjects, with a mean age of 63 years, were divided into seven treatment groups and the study was conducted at five locations throughout Sweden. The compliance was high, with 99% of the subjects completing the clinical part of the study.


No serious adverse event was reported in the Immunose™ FLU groups. The reported adverse events were mostly mild or moderate. A tolerability evaluation measuring discomfort at the administration site showed mild and transient experiences, lasting less than two hours.


With this study, the safety database has expanded to a total of over 400 subjects for the platform technology Endocine™.


The data put us exactly where we want to be for our further development and in our hunt for the next vaccine project, says Dr. Hans Arwidsson, CEO.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Does Indian Pharma lack an innovation-friendly ecosystem?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls